Epristeride (SKF-105,657, ONO-9302) is a selective, transition state, non-competitive inhibitor of the type II isoform of the enzyme 5α-reductase, similarly to finasteride and turosteride. It was under development for the treatment of benign prostatic hyperplasia and acne vulgaris by SmithKline Beecham (now GlaxoSmithKline), and reached phase III clinical trials in the United States, United Kingdom, and Japan, but ultimately was never marketed.

CAS：119169-78-7
中文别名：(17Β)-17-[[(1,1-二甲基乙基)氨基]羧基]雄甾-3,5-二烯-3-羧酸;17b-(N-叔丁基氨基甲酰基)雄甾-3,5-二烯-3-羧酸;依普甾胺;
英文别名：ONO-9302;Epiristeride;(17b)-17-[[(1,1-dimethylethyl)amino]carbonyl]-androsta-3,5-diene-3-carboxylic acid;17-n-tert-butylcarboxamide androst-3,5-diene-3-carboxylic acid;EPRISTERIDE(SUBJECTTOPATENTFREE);EPRISTERIDE UV;
分子式：C25H37NO3
分子量：399.566
精确质量：399.277
Psa：66.4
Logp：5.4919

UNII：39517A04PS

密度：1.13g/cm3
沸点：596ºC at 760mmHg
闪点：314.3ºC
折射率：1.563
蒸汽压：0mmHg at 25°C

生产方法
3-氧雄甾-4-烯-17β-羧酸甲酯(Ⅰ)经三溴化磷在冰乙酸中处理,转化为化合物(Ⅱ),再水解为化合物(Ⅲ)。先和草酰氯反应,再加叔丁胺经急冷而得化合物(Ⅳ)。(Ⅳ)经乙基溴化镁处理,再加入仲丁基锂,并通二氧化碳进行卤金属交换反应,即得依立雄胺粗品。粗品可在乙酸乙酯中加热精制。 睾酮还原酶抑制剂。
用途
睾酮还原酶抑制剂。